BUSINESS
After Entresto Flop, Hopes Grow for SGLT2 Inhibitors as HFpEF Treatments
October 16, 2019
Expectations are growing for SGLT2 inhibitors as treatments for heart failure with preserved ejection fraction (HFpEF) after Novartis’ Entresto (sacubitril + valsartan) failed to meet its primary goal in a PIII trail for that use.…

LATEST

October 16, 2019
In the latest move to reduce its debt load, Takeda Pharmaceutical has struck a US$200 million-plus deal to divest some 30 non-core assets marketed in emerging markets, including non-prescription drugs, to Switzerland’s Acino.The 30-or-so products subject to the deal are…
October 16, 2019
Astellas Pharma has agreed to sell three antiemetic and hypertension drugs marketed in Asia to its Japanese peer Daiichi Sankyo for 9.6 billion yen, the two companies said on October 15. Their combined sales totaled some 5 billion yen in…
October 16, 2019
Japanese patch drug powerhouse Hisamitsu Pharmaceutical said on October 15 that HP-3070 (asenapine) is now approved in the US under the brand name of Secuado as the first and only transdermal schizophrenia treatment in the country.The approval, which was granted…
By Yoshinori Sagehashi

With snowballing healthcare spending and the emergence of new modalities of treatments, discussions are heating up around revisiting the scope of health coverage on pharmaceuticals, with the Ministry of Finance (MOF) and payers advocating the mantra of “large risks with…

By Yoshinori Sagehashi

As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…

By Reiji Anasako

Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…

By Reiji Anasako

Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Philip Carrigan

In my home country of Australia, there is a famous candy called “Minties”. Minties has a long-running advertising campaign, presenting comical situations, with the caption, “It’s moments like these.” The phase has become part of the Aussie vernacular, meaning in…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA